Equillium to present at the svb leerink virtual global healthcare conference

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the svb leerink virtual global healthcare conference, taking place february 14 – 18, 2022. bruce steel, equillium's chief executive officer, and steve connelly ph.d., equillium's chief scientific officer, will pro
EQ Ratings Summary
EQ Quant Ranking